Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2015 / Articles / Jun / Mind the Gap
Manufacture Quality & Compliance

Mind the Gap

Some drug shortage prevention plans fail, while others succeed. Why? ISPE helps companies find the answer

By Stephanie Vine 06/02/2015 1 min read

Share

With the prevalence of drug shortages on the rise, the International Society for Pharmaceutical Engineering (ISPE) has stepped in to offer a helping hand by developing the Drug Shortages Prevention Plan (DSPP). The plan is based on a drug shortages survey performed in 2013, which pointed to several key factors to avoid shortages, including developing quality systems and strong management controls. Often, drug shortages are attributed to an excessive number of recalls, unavailable materials or poor product quality, but ISPE asserts the issue usually runs deeper than that, and relates to a company’s overall system of capabilities, controls and culture. Regional economic issues also play a part, but the ISPE plan focuses on what companies can do internally to prevent drug shortages.

“We are developing a Gap Analysis Tool to succinctly analyze – case by case – the risk of drug shortage causes, to aid in the development of mitigation plans,” says François Sallans, Chair of the ISPE Drug Shortages Task Team. Avoiding drug shortages is a complex task and even companies that have a prevention plan in place can fall victim to shortages if they don’t cover all the bases.

Sallans explains, “The ISPE Drug Shortages Prevention Plan is organized around a ‘six dimension’ framework:

  1. Corporate Quality Culture
  2. Robust Quality System
  3. Metrics
  4. Business Continuity Planning
  5. Communication with Authorities
  6. Building Capacity
The intention is for a company to first use the DSPP to look more holistically across their supply chain and challenge their current processes, systems and practices, and then use the Gap Analysis Tool to analyze the risks.”

Six Dimensions of Drug Shortage Prevention
Corporate Quality Culture: Driving the overall quality of a product throughout its lifecycle by focusing on cross-functional cooperation, management controls and problem escalation, and communication and transparency. Robust Quality Systems: Developing strategies across key elements such as governance, culture and management controls, as well as improving production and process-related factors. Metrics: Putting metrics in place to determine the performance of the quality system, as well as the supply chain and culture. Business Continuity Planning: Ensuring continuity of supply by building redundancy, implementing a robust quality system and testing and monitoring potential issues within the supply chain. Communication with Authorities: Working with regulators when facing a shortage can help management make the right decisions to allow solutions to be developed and implemented quickly. Building Capability: Implementing the processes of the DSPP relies upon the capabilities of the company’s personnel.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

Innovating Pharmaceutical Packaging
Quality & Compliance Supply Chain
Innovating Pharmaceutical Packaging

March 25, 2025

3 min read

Michiel van den Berg sheds light on the challenges and opportunities facing the industry as it adapts to new materials and regulatory requirements, offering expert insights into the future of pharmaceutical packaging.

AI Approach to Transdermal GLP-1s
Advanced Medicine Bioprocessing - Single Use Systems Bioprocessing - Upstream & Downstream Dosage Forms Contract Manufacturing Services Biosimilars Packaging Process Control Supply Chain Quality & Compliance
AI Approach to Transdermal GLP-1s

February 25, 2025

3 min read

How do you design, refine, and optimize novel GLP-1 drugs that could improve patient experiences? With a computer, of course.

Using the Right Excipients to Mitigate Nitrosamine Formation
Formulation Quality & Compliance Small Molecules
Using the Right Excipients to Mitigate Nitrosamine Formation

January 21, 2025

3 min read

In 2018, nitrosamines were discovered in some pharmaceuticals. The industry has since been under pressure to reduce the risks in both in-development and on-market drug products.

Ambition, Innovation, Impact: The Future of Cleanroom Standards
Process Control Quality & Compliance Standards & Regulation
Ambition, Innovation, Impact: The Future of Cleanroom Standards

December 4, 2024

5 min read

The rocket-fueled dreams of a young engineer applied to the cleanroom industry. Sitting down with Kevin Kyle, CEO, Germfree, who shares insights on the dynamic landscape of cleanroom design and deployment.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.